Limits...
CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2-neu-positive breast cancer.

Sengupta S, Rojas R, Mahadevan A, Kasper E, Jeyapalan S - Oxf Med Case Reports (2015)

Bottom Line: Nervous system relapse of patients with advanced HER2-neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases.Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response.We evaluated CPT-11 and bevacizumab, which can both cross the blood-brain barrier, as combination therapy to treat HER2-neu-positive breast cancer with brain metastases.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Neurology , Harvard Medical School, Beth Israel Deaconess Medical Center , Boston, MA , USA.

ABSTRACT
Nervous system relapse of patients with advanced HER2-neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases. Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response. We evaluated CPT-11 and bevacizumab, which can both cross the blood-brain barrier, as combination therapy to treat HER2-neu-positive breast cancer with brain metastases.

No MeSH data available.


Related in: MedlinePlus

Patient 3: MRI scans post contrast shown pre- and post-treatment, note scans were taken ∼3 months apart.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664841&req=5

OMV010F3: Patient 3: MRI scans post contrast shown pre- and post-treatment, note scans were taken ∼3 months apart.


CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2-neu-positive breast cancer.

Sengupta S, Rojas R, Mahadevan A, Kasper E, Jeyapalan S - Oxf Med Case Reports (2015)

Patient 3: MRI scans post contrast shown pre- and post-treatment, note scans were taken ∼3 months apart.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664841&req=5

OMV010F3: Patient 3: MRI scans post contrast shown pre- and post-treatment, note scans were taken ∼3 months apart.
Bottom Line: Nervous system relapse of patients with advanced HER2-neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases.Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response.We evaluated CPT-11 and bevacizumab, which can both cross the blood-brain barrier, as combination therapy to treat HER2-neu-positive breast cancer with brain metastases.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Neurology , Harvard Medical School, Beth Israel Deaconess Medical Center , Boston, MA , USA.

ABSTRACT
Nervous system relapse of patients with advanced HER2-neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases. Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response. We evaluated CPT-11 and bevacizumab, which can both cross the blood-brain barrier, as combination therapy to treat HER2-neu-positive breast cancer with brain metastases.

No MeSH data available.


Related in: MedlinePlus